Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

This study has been completed.

Sponsor:

Collaborators:

Duke University

Medical University of South Carolina

Information provided by (Responsible Party):

Erimos Pharmaceuticals

ClinicalTrials.gov Identifier:

NCT00057512

First received: April 3, 2003

Last updated: February 20, 2016

Last verified: January 2006

History of Changes

Purpose

The purpose of this study will be to determine the safety and tolerability of intratumoral M4N. Patients suffering from cancer of the head and neck that is recurrent after primary treatment with surgery, radiation therapy, and/or chemotherapy may be eligible. The design is a Phase 1 dose escalation study of M4N administered intratumorally once weekly, initially for three weeks. Dose will be escalated on the starting schedule to a target of 20 mg/cm3 tumor volume and then, new patient cohorts will have their schedule extended to weekly M4N for 4 weeks. Dose escalation will continue, assuming tolerability, so that cohorts will be treated for 6 weeks, and finally, 8 weeks.

Condition	Intervention	Phase
Head and Neck Neoplasms	Drug: M4N	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

Resource links provided by NLM:

MedlinePlus related topics: Head and Neck Cancer

U.S. FDA Resources

Further study details as provided by Erimos Pharmaceuticals:


Enrollment:	9
Study Start Date:	January 2003
Study Completion Date:	December 2003
Primary Completion Date:	December 2003 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Intratumoral M4N The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.	Drug: M4N Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume. Other Name: Tetra-O-Methyl Nordihydroguaiaretic Acid or EM-1421

Detailed Description:

Study data collected will include pre-study demographics and measurements, treatment compliance, efficacy determined by tumor measurements, M4N levels in blood for pharmacokinetics, serum and biochemical determinations, hematology determinations, and patient vital signs.

Eligibility


Ages Eligible for Study:	18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female patients ≥ 18 years of age.
Patients with documented histologic evidence of head and neck cancer with clinically measurable disease. Head and neck cancer could have been recurrent after primary treatment with surgery, radiation therapy and/or chemotherapy.
Measurable tumor by direct inspection, photography, or by imaging (CT scan or MRI).
Life expectancy of at least 3 months in the Investigators' opinion.
Negative pregnancy test if in women of childbearing potential within 1 week of starting therapy.
Patients had provided written informed consent to participate in study.
ECOG Performance Status of 0, 1, or 2.
Absolute neutrophil ≥ 1500/uL, hemoglobin ≥ 8 gm%, platelets ≥ 50,000/uL,
ALT/AST ≤ 3 x ULN (upper limit of the normal range), bilirubin ≤ 1.5 x ULN and creatinine ≤ 1.5 x ULN, PT and PTT within normal limits.

Exclusion Criteria:

Women who were pregnant or nursing.
Women of child bearing potential who were unwilling to use an adequate method of contraception during the course of the study.
Treatment with prior investigational agent within 30 days of entering the study.
Patients who are unable to comply with the study requirements.
Patients with known sensitivity to any of the study medication components.
Patients not consenting to photography.
Patients with tumors that have enveloped the carotid artery or whose anatomy had been distorted such that in the Investigator's opinion present high-risk of perforation or compromise during injection.
Prior chemotherapy, radiation therapy, or surgery for the primary carcinoma within 30 days of dosing and/or had not recovered from prior therapy toxicities.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057512

Locations


United States, South Carolina
MUSC
Charleston, South Carolina, United States, 29475

Sponsors and Collaborators

Erimos Pharmaceuticals

Duke University

Medical University of South Carolina

More Information


Responsible Party:	Erimos Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00057512 History of Changes
Other Study ID Numbers:	M4N001
Study First Received:	April 3, 2003
Last Updated:	February 20, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Additional relevant MeSH terms:


Head and Neck Neoplasms Neoplasms Neoplasms by Site Masoprocol Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Lipoxygenase Inhibitors	Enzyme Inhibitors Cyclooxygenase Inhibitors Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Antirheumatic Agents

ClinicalTrials.gov processed this record on July 19, 2017

To Top